Biopharmaceutical company Curacyte AG, which is backed by firms such as TVM Capital, AlpInvest Partners and IKB Venture Capital, has sold its subsidiary Curacyte Discovery GmbH to Medicines Co for an upfront payment of EUR 14.5m and additional payments based on the achievement of clinical milestones.
Charcoal and natural additives company saw final bids from two banks and one direct lender
VCs including the Swiss Entrepreneurs Fund, BtoV and Ringier Digital Ventures also participated
Around 40 existing and new LPs, including British Patient Capital and the EIF, participated
Fund will invest in buyouts, recapitalisations and carve-outs of both profitable and underperforming businesses